Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013581

— · cohortA1

a38c0e6d-61c9-5789-a871-905d746bd7bb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.620
  • INTERFERON_GAMMA_RESPONSE+0.620
  • ALLOGRAFT_REJECTION+0.580
  • IL6_JAK_STAT3_SIGNALING+0.480
  • E2F_TARGETS+0.460
  • G2M_CHECKPOINT+0.430
  • COMPLEMENT+0.360
  • MITOTIC_SPINDLE+0.330
  • INFLAMMATORY_RESPONSE+0.310
  • IL2_STAT5_SIGNALING+0.240

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.340
  • NOTCH_SIGNALING-0.320
  • MYOGENESIS-0.300
  • ESTROGEN_RESPONSE_LATE-0.280
  • CHOLESTEROL_HOMEOSTASIS-0.260
  • ANGIOGENESIS-0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
  • KRAS_SIGNALING_DN-0.200
  • TGF_BETA_SIGNALING-0.190
  • BILE_ACID_METABOLISM-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BSR_11_0107_E3_S77
breast-umap@18
—D0.860
2SRR10842377
melanoma-umap@29
——0.858
3aefb974b-c7d9-47f0-8f18-9346c087ea64
melanoma-umap@29
——0.847
4SRR8613787
breast-umap@18
—D0.844
5695836ff-c54b-47bf-8a29-5224811afa7e
colon-landscapes@1
——0.844
6SRR8613734
breast-umap@18
—D0.843
7TCGA-EW-A1OV-01A-11R-A144-07
breast-umap@18
—D0.835
8TCGA-21-1070-01A-01R-A96U-41
lung-landscapes@6
—cohortSQ10.835
9TCGA-AO-A128-01A-11R-A10J-07
breast-umap@18
—D0.833
10C3N-02922
lung-landscapes@6
—cohortMD20.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.620Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.620Idelalisib— uncovered
ALLOGRAFT_REJECTION0.580Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.480Inavolisib— uncovered
E2F_TARGETS0.460Inavolisib— uncovered
G2M_CHECKPOINT0.430Inavolisib— uncovered
COMPLEMENT0.360Inavolisib— uncovered
MITOTIC_SPINDLE0.330Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.310Idelalisib— uncovered
IL2_STAT5_SIGNALING0.240Idelalisib— uncovered
APOPTOSIS0.220Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.200Inavolisib— uncovered
DNA_REPAIR0.190Idelalisib— uncovered
KRAS_SIGNALING_UP0.160Inavolisib— uncovered
MYC_TARGETS_V10.150Inavolisib— uncovered
P53_PATHWAY0.080Idelalisib— uncovered
GLYCOLYSIS0.060Inavolisib— uncovered
FATTY_ACID_METABOLISM0.030Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.020Inavolisib— uncovered